ACE inhibitors, AR Blockers and NCOV-19

One of the first studies investigating the association between ACE-inhibitors, AR- blockers, and outcome in NCOV-19 has recently been published. Although based on a relatively small sample size, the conclusions do appear to be encouraging: "We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs..... This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension."

Interesting to see if further studies are in agreement.

Stay well everyone.

tandfonline.com/doi/full/10...

[Prada47]

That's a reasonable assessment thanks for that.

Stay Safe Stay Well

[Chappychap]

Thanks for posting